Eyenovia (NASDAQ:EYEN) Rating Lowered to Hold at ValuEngine

Eyenovia (NASDAQ:EYEN) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a report issued on Thursday, ValuEngine reports.

Other equities research analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of Eyenovia from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a research report on Friday, August 16th. HC Wainwright decreased their price objective on shares of Eyenovia from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, October 30th.

Eyenovia stock opened at $2.81 on Thursday. Eyenovia has a 52 week low of $2.40 and a 52 week high of $6.98. The firm’s 50-day simple moving average is $3.29 and its 200 day simple moving average is $4.00.

Eyenovia (NASDAQ:EYEN) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.03. Analysts forecast that Eyenovia will post -1.6 EPS for the current fiscal year.

An institutional investor recently raised its position in Eyenovia stock. Vanguard Group Inc. raised its position in Eyenovia Inc (NASDAQ:EYEN) by 72.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,748 shares of the company’s stock after purchasing an additional 58,697 shares during the period. Vanguard Group Inc. owned about 0.85% of Eyenovia worth $601,000 at the end of the most recent reporting period. 8.90% of the stock is owned by institutional investors.

Eyenovia Company Profile

Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.

Read More: Can systematic risk be avoided?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.